期刊
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
卷 11, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s40164-022-00277-y
关键词
Tumor microenvironment; Heterogeneity; Immune checkpoint blockade; Immunotherapy
资金
- National Nature Science Foundation of China [82073147]
Tumor immunological heterogeneity plays a crucial role in the progression of disease and treatment response, especially in the field of immunotherapy. Recent studies using advanced sequencing and biopsy methods have shown the potential to investigate the complexity and clinical relevance of tumor immunological heterogeneity.
During the course of tumorigenesis and subsequent metastasis, malignant cells gradually diversify and become more heterogeneous. Consequently, the tumor mass might be infiltrated by diverse immune-related components, including the cytokine/chemokine environment, cytotoxic activity, or immunosuppressive elements. This immunological heterogeneity is universally presented spatially or varies temporally along with tumor evolution or therapeutic intervention across almost all solid tumors. The heterogeneity of anti-tumor immunity shows a profound association with the progression of disease and responsiveness to treatment, particularly in the realm of immunotherapy. Therefore, an accurate understanding of tumor immunological heterogeneity is essential for the development of effective therapies. Facilitated by multi-regional and -omics sequencing, single cell sequencing, and longitudinal liquid biopsy approaches, recent studies have demonstrated the potential to investigate the complexity of immunological heterogeneity of the tumors and its clinical relevance in immunotherapy. Here, we aimed to review the mechanism underlying the heterogeneity of the immune microenvironment. We also explored how clinical assessments of tumor heterogeneity might facilitate the development of more effective personalized therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据